News | November 10, 2021
Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
The company has tied up with OrbiMed as a financial partner for global reach
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Subsidiary has received one inspectional observation in Form 483
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Emcure Pharmaceuticals API facility
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Subscribe To Our Newsletter & Stay Updated
